ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 145 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,396,097 | -53.4% | 1,204,538 | -16.4% | 0.03% | -52.5% |
| Q2 2023 | $13,723,543 | -39.7% | 1,440,036 | -30.4% | 0.06% | -47.3% |
| Q1 2023 | $22,760,947 | +34.3% | 2,069,177 | +80.7% | 0.11% | +8.7% |
| Q4 2022 | $16,948,116 | +528.9% | 1,145,143 | +712.1% | 0.10% | +505.9% |
| Q3 2022 | $2,695,000 | – | 141,002 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $296,569,000 | 22.84% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $111,937,000 | 7.03% |
| Pivotal bioVenture Partners Investment Advisor LLC | 671,716 | $18,895,000 | 6.23% |
| Omega Fund Management, LLC | 640,199 | $18,009,000 | 2.70% |
| Orbimed Advisors | 6,073,850 | $170,857,000 | 1.50% |
| Vivo Capital, LLC | 867,170 | $24,393,000 | 1.09% |
| Octagon Capital Advisors LP | 100,000 | $2,813,000 | 0.98% |
| Altium Capital Management LP | 62,962 | $1,771,000 | 0.66% |
| RA Capital Management | 1,165,184 | $32,777,000 | 0.46% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 8,505 | $239,000 | 0.14% |